v3.26.1
Segment Information (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Information            
Number of segments | segment         1  
Interest income $ 160,233   $ 191,395   $ 298,033 $ 379,007
Net loss (14,820,815) $ (17,606,382) (6,220,058) $ (5,537,069) (32,427,198) (11,757,127)
Single reportable segment            
Segment Information            
Program expenses related to clinical-stage product candidates (10,707,646)   (4,228,642)   (26,286,245) (8,445,857)
Program expenses related to preclinical and discovery programs (146,915)   (49,714)   (343,909) (80,313)
Program expenses related to clinical manufacturing candidates (144,264)       (415,094)  
Personnel-related expenses (including stock-based compensation) (2,484,630)   (1,496,642)   (3,758,951) (2,894,516)
General and administrative professional and consultant fees (668,764)   (292,649)   (1,159,339) (737,514)
Other segment items (225,493)   (203,806)   (426,357) (395,934)
Interest income 160,233   191,395   298,033 379,007
Other non-cash income (expense) items (603,336)   (140,000)   (335,336) 418,000
Net loss $ (14,820,815)   $ (6,220,058)   $ (32,427,198) $ (11,757,127)
Segment Reporting, Other Segment Item, Composition, Description         1 Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses. 2 Other non-cash income (expense) items include the change in fair value of our liability classified warrants and expenses and fees incurred from issuance of warrants.